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In the staging of cancer, equivocal test results may occur in subjectively evaluated imaging
procedures whose interpretations raise the possibility ofmetastases but are toouncertain torule in
or rule out metastatic spread, and in tests whose repetitions in the same patient yield conflicting
results about dissemination. We assessed the frequency and prognostic correlates of test results
giving equivocal evidence of disseminated (Stage IV) disease in an inception cohort of 280
patients receiving initial treatment for prostatic cancer between 1973-76.
Among tests used for clinical staging, lymphangiograms (equivocal in 28 percent of tested
patients), bone scans (equivocal in 25 percentoftested patients), and bone radiographs (equivocal
in 20 percent of tested patients) most frequently yielded interpretations that equivocally
suggested metastatic spread. Eighty-three (45 percent) of the 185 patients without clear-cut
dissemination (Stages I-III) had at least one equivocal test result that suggested dissemination
and that remained unresolved at the time ofselection oftherapy. Five-year survival (30 percent)
for the 20 patients with local extracapsular spread (Stage III) and multiple equivocal results
suggesting dissemination was identical to that for patients with clear-cut dissemination. In
contrast, other patients with equivocal dissemination in Stages I-III had survival rates similar to
those patients in the same stage and lacking equivocal dissemination.
Unresolved equivocal staging results frequently complicate management decisions for patients
with prostatic cancer. Survival analyses aid these decisions by demonstrating that equivocal
findingsofdissemination are prognostically unimportant unless they are multipleand occur in the
context ofunequivocal extracapsular spread.
INTRODUCTION
Diagnostic tests are used in the management of solid tumors to determine how far
the cancer has spread so that an appropriate therapy can be selected. Yet for the
majority of laboratory tests used for staging of cancer, such as radiographs and
radionuclide scans, the interpretation of complex patterns is required, and the
interpretation is frequently "possibly positive" or "possibly negative." Moreover, even
a test with results that are expressed on a dimensional scale may become equivocal ifit
yields both "normal" and "abnormal" results when performed on multiple occasions in
the same patient. But despite the well-known occurrence ofsuch equivocal results, and
despite the unsettling effect of these results upon clinical decision making, little is
known about their prevalence and their meaning.
In this paper we consider the prevalence and prognostic importance of equivocal
results from tests used in theclinical staging ofpatients with prostaticcancer. Prostatic
cancer was chosen for this analysis for two reasons. First, the staging of prostatic
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cancer relies to a great extent upon the results ofnon-invasive tests requiring subjective
interpretations [1]. Second, patients with prostatic cancer tend to be elderly and to
have associated conditions that may mimic cancer metastases [2]. For both these
reasons, the staging dilemmas created by equivocal results should be as pronounced for
prostatic cancer as for any cancer.
METHODS
Prognostic Staging ofProstatic Cancer
We classified patients according to the combined anatomic-serum prostatic acid
phosphatase system used for the Veterans Administration Cooperative Urological
Research Group (VACURG) studies of prostatic cancer [3]. In this system, patients
with a normal value for prostatic acid phosphatase are placed in Stage I ifthe cancer is
clinically unsuspected and if it is localized within the prostatic capsule, in Stage II if
the cancer is localized within the capsule but is clinically suspected, and in Stage III if
the cancer extends beyond the capsule but has not spread to the pelvic lymph nodes or
other distant sites. Patients who have an elevated value for serum prostatic acid
phosphatase or patients who have evidence of distant spread are placed in Stage IV.
When staging is determined on the basis of routine clinical tests and biopsies short of
an operative retroperitoneal dissection, the stage is referred to as the "clinical stage,"
and when staging is based additionally upon the results of a retroperitoneal dissection,
the stage is referred to as a "surgical stage" [4]. Since relatively few patients receive
complete surgical staging, our major focus in this paper is the influence of equivocal
staging results upon clinical staging. Moreover, since not all patients receive complete
clinical staging evaluations in routine practice, we gave patients a modified VACURG
stage in two circumstances. First, for patients who received no serum acid phosphatase
determinations, a clinical stage was determined on the basis of anatomic findings.
Second, for patients who received total serum acid phosphatase determinations rather
than prostatic serum acid phosphatase determinations, the stage was determined on
the basis of the total serum acid phosphatase.
To avoid bias in determining the clinical stage, it is necessary to ascertain the extent
ofdisease using only information accumulated up to a time in the clinical course that is
comparable for each patient. This time, which we refer to as "zero-time," was defined
as the inception of antineoplastic therapy for cancer of the prostate [5]. For the
purposes of this study, "antineoplastic therapy" included radical prostatic surgery,
radiotherapy, and hormonal therapy (estrogens or orchiectomy). When a decision was
made to give such antineoplastic therapy, zero-time was taken as the first day of the
therapy. If none ofthese therapies was given, but some non-radical surgical procedure
(e.g., transurethral resection ofthe prostate) was administered as palliative therapy for
cancer, the palliative therapy was considered the antineoplastic therapy. When
therapy was intentionally withheld after a diagnosis of prostatic cancer was made,
zero-time was taken as the date of the decision not to administer therapy. When no
antineoplastic therapy was given but no clear anti-therapeutic decision was made,
zero-time was the date ofthe histologic diagnosis ofprostatic cancer.
Assembly ofthe Patient Population
The patient population for this study comprised all patients with a histologic
diagnosis ofprostatic cancer confirmed during life and with zero-time events occurring
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at the Yale-New Haven Hospital (YNHH) between January 1, 1973, and December
31, 1976. The patient population was identified from three sources: the diagnostic
registry ofthe YNHH medical record room, the Connecticut Tumor Registry, and the
surgical pathology files ofYNHH. The search yielded the names of405 patients. After
inspection of medical records and of data made available by the Connecticut Tumor
Registry, 125 cases were excluded: 91 cases in which zero-time occurred at a hospital
other than YNHH; 16 cases in which zero-time occurred at YNHH but not during the
selection interval for the study; 12 cases for whom prostatic cancer was histologically
confirmed; and six cases in which prostatic cancer was histologically confirmed only as
a surprise diagnosis at necropsy. The remaining 280 patients are the subjects of this
report.
Collection ofthe Data
Data from YNHH medical records, supplemented when necessary by information
from the Connecticut Tumor Registry and from other sources such as other hospitals
and personal physicians, were extracted on to a form specially constructed to provide a
detailed account ofthechronologic development and course ofthe illness, together with
the formal reports ofall pertinent laboratory tests used to evaluate the patients before
therapy. Details of therapy as well as post-zero survival were recorded. Follow-up for
the patient population terminated as ofDecember 31, 1981. Complete follow-up at five
years after zero-time was available for 267 ofthe patients: thirteen patients were lost to
follow-up at post-zero intervals ranging from .01 year to 4.8 years. Data extraction was
performed by a research assistant who was "blinded" to the nature of the research
hypotheses.
Assessment ofEquivocal Results
Because findings ofdistant metastases constitute the most important source ofdata
arguing against radical antineoplastic therapy, the focus of this research was to
evaluate the importance and the impact oflaboratory results giving equivocal evidence
for distant metastases. For test results expressed as qualitative descriptions (e.g.,
radiographic procedures), a test result was regarded as equivocal if the description of
the result suggested that distant spread was possible, but could not be definitely
established. Accordingly, such expressions as "atypical of, but not inconsistent with
metastases," "equivocal evidence ofmetastases," "metastases cannot be ruled out," or
statements supplemented by a qualification that further tests were required to resolve
the diagnostic uncertainty were deemed equivocal. In contrast, statements indicating
that metastases were either at least "probable," or "unlikely" were considered
unequivocal. A test result was not considered equivocal ifone anatomic area that was
considered to be equivocal was accompanied by an additional area felt to represent
metastatic spread. For each type of serum acid phosphatase (total and prostatic
fraction) we considered the results to be equivocal if results both inside and outside of
the range of normal values were obtained. All assessments about equivocal vs.
non-equivocal results were made without knowledge ofpost-zero survival.
Evaluation ofEquivocal Data in the Context ofMultiple Test Results
When several tests were performed to evaluate theabnormality cited in an equivocal
test result, it was necessary to make decisions about whether the composite of the test
results remained equivocal for metastases. For equivocal results from tests which
3CLEMENS ET AL.
permit visual evaluation ofmetastases, we considered the equivocal results as resolved
to either metastasis or no metastasis, according to biopsy results for the corresponding
area.
In lieu of histological evaluation, if the same imaging test was repeated and one or
moreofthe results was regarded as equivocal for metastases, thecompositeofrepeated
tests was not considered equivocal unless all results were considered equivocal for
metastases or unless the repeated testing yielded unequivocal interpretations that were
conflicting (e.g., one result describing a definite metastasis and another result
describing no metastasis in the sameanatomicarea). Although equivocalcompositesof
repeated results could also result from conflicting unequivocal interpretations per se,
such ensembles ofrepeated results were not observed in our series.
Without biopsy evidence, an equivocal result by one test that was designated as
definite or probable metastasis by a different test was considered to be metastasis.
When an equivocal metastasis shown in one test was not interpreted as a metastasis in a
different test, we considered the composite interpretation for the anatomic area to be
negative for metastasis if the normal result was derived from a test that was more
sensitive in detecting metastases. In practice, this rule applied to the evaluation of
retroperitoneal and pelvic nodal metastases, for which we regarded lymphangiography
as more sensitive than intravenous pyelography, and to the evaluation of bone
metastases, for which we considered radionuclide studies to be more sensitive than
radiographs [6,7,8]. These rules for interpretating the results ofmultiple imaging tests
should have yielded a conservative estimate ofthe prevalence ofequivocal metastases,
since it is not necessarily true that an equivocal result of one imaging test can be
resolved by an additional, apparently clear-cut result obtained by repeating the same
test or by performing different imaging tests.
For the evaluation of multiple acid phosphatase determinations, we regarded the
serum prostatic acid phosphatase as the "gold standard" for determining serum acid
phosphatase. When both total and prostatic acid phosphatase values were ascertained,
we considered the serum acid phosphatase to be equivocal only if the serum prostatic
acid phosphatase values were conflicting (inside and outside the range of normal
values). When serum prostatic acid phosphatase values were not ascertained, we
considered the serum acid phosphatase to be equivocal if the serum total acid
phosphatase determinations were conflicting.
Prognostic Analyses ofEquivocalStagingResults
Because patients infrequently received biopsies to evaluate anatomic regions
containing equivocal evidence of metastases, and because possible dissemination
cannot be directly refuted by a negative biopsy result when the evidence for
dissemination consists of equivocally elevated values for serum acid phosphatase, we
assessed the prognostic correlates of equivocal dissemination. In this analysis, we
compared the survival of patients with and without equivocal results for-disseminated
cancer, controlling for the degree ofspread evident fromunequivocal staging data. We
chose five-year survival as the target for survival analyses because the median survival
for patients in our series was approximately five years, and because five-year survival
rates commonly form the basis for prognostic and therapeutic evaluations ofprostatic
carcinoma. Differences in five-year survival rates were statistically appraised with
chi-square tests, interpreted in a two-tail fashion, for 2 x 2 contingency tables in which
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TABLE 1
Five-Year Survival Rates for the Study Population
According to Clinical Stage
Number (%)
Clinical Stagea Number in Stageb Surviving Five Years
I 50 37 (74)
II 72 51(71)
III 54 28 (52)
IV 91 27 (30)
Total 267 143 (54)
aDefined according to criteria described in the text
b' 3 patients for whom five-year follow-up was incomplete are
excluded.
each expected cell frequency was >5. For 2 x 2 tables in which smaller frequencies
were expected, the Fisher exact test was employed.
RESULTS
Characteristics ofthe Study Population
All 280 patients had adenocarcinoma of the prostate. The median age for the study
population was 70 years. Approximately equal numbers of patients met the eligibility
requirements for the study during each of the four years constituting the selection
interval. Five-year survival rates for the 267 patients with complete follow-up are given
in Table 1. When patients were classified by clinical stage according to unequivocal
staging results, five-year survival rates ranged from 74 percent in Stage I to 30 percent
in Stage IV.
Prevalence ofEquivocal Results Suggesting Metastatic Spread ofCancer
During the era in which the study population was treated, the basic tests used to
detect distant metastases in clinical staging included serum acid phosphatase (total
and prostatic fraction), radiographs and radionuclide scans for the evaluation of bone
metastases, intravenous pyelography and lymphangiography to assess pelvic lymph
node metastases, and chest radiographs todetect pulmonary metastases. Table 2 shows
the number of patients receiving each of these basic tests and the number of patients
having equivocal evidence for metastases according to each typeoftest result. In Table
2 test results that were equivocal by one type of test, but which were resolved by the
results ofdifferent tests, are still considered equivocal, so that the overall frequency of
equivocal results provided by each type of staging test can be appreciated. Strikingly
high frequencies of equivocal results, occurring in excess of 20 percent of patients
receiving the test, were found for bone scans, lymphangiograms, and bone radiographs.
Equivocal results were less frequent, but not uncommon, for the remainder ofthe tests.
Table 3 shows the staging ambiguities created by equivocal findings of metastatic
spread that remained unresolved at zero-time. Eighty-three (30 percent) of the 280
patients had at least one equivocal result which was unresolved at zero-time and which
created uncertainty as to whether the cancer was non-disseminated (Stages I-III) or
disseminated (Stage IV). The proportion ofpatients having such equivocal evidence of
dissemination increased with the clinical stage determined on the basis ofunequivocal
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TABLE 2
Frequency of Equivocal Evidence of Distant Cancer by Individual Staging Tests
Number (%) of
Patients Receiving Test
Number ofPatients in Whom Test Yielded
Type ofTest Receiving Test Equivocal Results
Serum acid phosphatase'
(total) 249 5 (2) a
Serum acid phosphatase
(prostatic fraction) 240 19 (8)
Bone scan 119 30 (25)
Bone radiograph 256 52 (20)
Intravenous pyelogram 227 13 (6)
Lymphangiogram 53 15 (28)
Chest radiograph 259 29 (11)
aEquivocal values for total serum acid phosphatase and for prostatic serum acid
phosphatase occurred when more than one result was obtained with a mixture of
normal (.1.5 International Units for prostatic acid phosphatase and <8.0 Interna-
tional Units for total acid phosphatase) and abnormal results.
information, reaching a maximum of 63 percent of patients in whom all unequivocal
data indicated Stage III disease. Among the 83 patients with unresolved ambiguities
about dissemination at zero-time, the ambiguities were attributable to bone studies in
51 patients (61 percent), to lymph node studies in 22 patients (27 percent), to lung
radiographs in 16 patients (19 percent), and to acid phosphatase determinations in 15
patients (18 percent). Ten ofthe patients in the series received biopsies to resolve these
major uncertainties about distant metastases. One patient with equivocal bone studies
received a bone biopsy which revealed no tumor, and nine patients with equivocal
lymph node studies underwent subsequent surgical staging with retroperitoneal node
exploration. Only one of these nine patients had demonstrable nodal metastases upon
exploration.
Survival Correlates ofEquivocal Metastatic Spread
Table 4 compares five-year survival rates for patients whose only evidence for
metastatic spread was equivocal and for patients lacking such equivocal data. Within
each clinical stage, defined on the basis of unequivocal staging data, no statistically
significant differences in survival were apparent between patients having and patients
TABLE 3
Frequency of Equivocal Results Causing Ambiguity Between a
Non-Disseminated and Disseminated Stage
Number (%) of
Stage Based on Number ofPatients Patients with
Unequivocal Data in Stage Equivocal Dissemination
I 55 14 (25)
II 74 34 (46)
III 56 35 (63)
IV 95
Total 280 83 (30)
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TABLE 4
Five-Year Survival According to Unequivocal Clinical Stage
and to the Presence or Absence of Equivocal Dissemination
Proportion
Clinical Stage Based on Equivocal (%) Surviving
Unequivocal Results Dissemination Five Yearsa
I No 29/39 (74)***
Yes 8/11 (73)**
II No 27/39 (69)***
Yes 24/33 (73)***
III No 13/21 (62)**
Yes 15/33 (45)
IV __b 27/91 (30)
**p < .01 ***p < .001 for the differences between five-year survival rate for the
cited stage and that for Stage IV
'I3 patients with incomplete follow-up at five years excluded from survival
calculations
bEquivocal findings not considered since they did not affect assessment of whether
dissemination was present or absent
lacking equivocal metastases. For patients in Stages I and II, the five-year survival
rates were virtually identical, irrespective ofequivocal dissemination, and the rates of
survival in patients with equivocal dissemination were significantly higher than rates
for patients having clear-cut dissemination (Stage IV). In contrast, the survival rate
for patients in Stage III with equivocal dissemination was between the survival rate for
Stage III patients lacking equivocal dissemination and the rate for Stage IV patients.
We also attempted to identify additional characteristics ofequivocal dissemination
that delineated a subgroup whose survival was similar to that for patients in Stage IV.
Analysis ofsurvival according to the particular site ofthe equivocal results (e.g., bone,
lymph nodes, lungs) failed to identify such a subgroup. When we classified patients
according to the number of sources of equivocal evidence for metastases-where a
"source" is defined as an anatomic site with an equivocal metastasis or as an equivocal
ensemble of values for serum acid phosphatase-patients in Stages I and II had
virtually identical rates ofsurvival regardless ofthe number of sources ofevidence for
equivocal metastases (Table 5). Similarly, patients in Stage III with a single source of
evidence for equivocal dissemination had a survival rate similar to that ofthe patients
in Stage III without any equivocal evidence of dissemination. However, patients in
Stage III with more than one source of evidence for equivocal dissemination had a
survival rate that was virtually identical to the survival rate ofpatients in Stage IV.
DISCUSSION
Our data demonstrate that equivocal results obtained in the course of the clinical
staging ofprostatic cancer create frequent ambiguities in assessing whether the cancer
has become disseminated. Among the 185 patients in whom unequivocal staging
results demonstrated no more than contiguous extracapsular extension, 83 (45
percent) had additional unresolved equivocal evidenceofdistant metastases at thetime
that antineoplastic therapy was selected.
Our results also demonstrate that since patients with equivocal staging data
uncommonly receive definitive histologic evaluations ofequivocal sites (ten patients in
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TABLE 5
Five-Year Survival According to Unequivocal Clinical Stage and to the Presence
and Number of Sources of Equivocal Dissemination
Clinical Stage Number ofSources Proportion (%)
Based on Equivocal of Equivocal Surviving
Unequivocal Results Dissemination Dissemination' FiveYears'
I No 29/39 (74)
Yes 1 3/5 (60)
Yes >1 5/6 (83)
II No 27/39 (69)
Yes 1 8/12 (75)
Yes >1 16/21 (76)
III No 13/21 (62)
Yes 1 9/13 (69)*
Yes >1 6/20 (30)
IV 27/91 (30)
*p < .05 for thedifference in five-year survival rates between Stage III patients with
one source of equivocal metastases and Stage III patients with >1 sources of
equivocal metastases
aDefined in text
bl3 patients with incomplete follow-up at five years are excluded from this analysis.
our series), correlations between such equivocal staging results and corresponding
results from invasive tests are susceptible to giving a biased impression of the "true"
diagnostic meaning of equivocal metastases. This infrequency of concurrent gold-
standard testing made it desirable to evaluate the implications ofequivocal metastases
indirectly through the analysis of survival. Our analysis suggests that for patients in
whom all unequivocal evidence suggests only intracapsular disease (Stages I and II),
equivocal results fordissemination do not portend survival that differs quantitatively or
statistically from survival associated with clearly negative results for dissemination.
For patients in whom all unequivocal evidence indicates extracapsular but not distant
spread (Stage III), a single source ofevidence for dissemination also corresponds to a
rate ofsurvival that is no different from the rate for patients with negative evaluations,
but multiple equivocalities predict a rate of survival that is identical to the rate for
patients with clear-cut metastases.
Biological andPragmatic Implications ofEquivocal Metastatic Spread
Because isolated equivocal metastases are prognostically unimportant and multiple
equivocal metastases portend poor survival in the setting of Stage III disease, it is
tempting to speculate that any equivocal metastases in Stages I-II disease and isolated
equivocal metastases in Stage III disease usually represent false-positive metastases,
whereas multiple equivocal metastases in Stage III disease usually correspond to true
dissemination. However, we do not believe that it is possible to deduce from survival
analyses whether equivocal metastases in fact represent true dissemination. Several
workers have established that the likelihood of inapparent dissemination increases as
the extent of local spread progresses from Stages I to III [9,10,11]. In our series we
observed correspondingly higher frequencies of both single and multiple equivocal
metastases with increasing degrees of unequivocal local spread (Table 5). This
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parallelism might suggest an alternative explanation for our findings: equivocal
metastases may represent true metastases, and the prognostic correlates observed in
our study merely reflect variations in the biological aggressiveness of the dissemina-
tion.
Despite our inability to draw conclusions about whether equivocal metastases
represent true metastases, the relationships in our prognostic analyses have substantial
practical importance. In the management of individual patients, knowledge of the
prognostic implications of equivocal test results may assist selection of appropriate
therapies and tests, and can provide reassurance to both physicians and patients. In
addition, our data indicate that studies of therapies for prostatic cancer must arrange
for appropriate classification and analysis of equivocal staging results to assure that
the therapies are compared in patients with equivalent baseline prognoses and to
enable extrapolation ofthe results to patients encountered in clinical practice.
Limitations ofthe Data
Since wedepended upon routine readings oftests reported qualitatively in diagnostic
test reports, it was impossible to discern which particular features of the results made
them "equivocal." Moreover, there may be wide variations in the meaning that
different physicians attach to the expressions which we used to define "equivocal."
Thus, strictly speaking, our results pertain to equivocalities described in laboratory
reports rather than equivocalities as interpreted by clinicians.
Another limitation arises from the changing technologies used to stage the patients.
For the assessment of distant metastases, substantial changes have occurred in the
assessment of lymph node metastases with the introduction ofcomputerized tomogra-
phy and transcutaneous thin needle biopsies [12]. Moreover, surgical staging has
become more common, although it has not become universal because ofthe substantial
morbidity and mortality associated with this form ofstaging [13]. On the other hand,
methods for evaluation of bone metastases have not changed, and although more
sensitive methods ofassaying serum acid phosphatase have become available, they are
not in widespread use. Since the problem ofequivocal results for these newer tests has
not been addressed, it is difficult to predict what impact these technological changes
have had on the prevalence and prognostic correlates of equivocal dissemination.
Nevertheless, because of the continued substantial reliance on non-invasive tests,, it
would be surprising ifchanging technologies havesignificantly diminished the problem
ofequivocal staging results in the management ofprostatic cancer.
Future Research
Our study emphasizes the need for prospective research into the definition of which
features make tests seem equivocal for metastases rather than clearly positive or
negative. Because ofthe high frequency ofequivocal metastases, it is also important to
understand how clinicians incorporate equivocal data into management plans and why
clinicians so rarely perform tests to resolve the equivocalities. With rapidly changing
technologies, it is also important to evaluate the impact of newer techniques both in
creating and in resolving ambiguities in staging. Finally, because it is unlikely that the
problem of equivocal results in staging is limited to prostatic cancer, the problem of
equivocal results in staging should be assessed for other cancers.
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